Erasca (ERAS)
(Delayed Data from NSDQ)
$2.24 USD
+0.27 (13.71%)
Updated May 20, 2024 04:00 PM ET
After-Market: $2.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ERAS 2.24 +0.27(13.71%)
Will ERAS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ERAS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ERAS
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
ERAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should SNDL (SNDL) be in Your Portfolio Ahead of Q1 Earnings?
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings
Other News for ERAS
Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
Erasca’s Promising Pipeline and Solid Funding Outlook Balanced by Caution: A Hold Rating
Erasca price target lowered by $3 at H.C. Wainwright, here's why
Erasca’s Strategic Advances and Financial Fortitude Merit a Buy Rating
Optimistic Outlook for Erasca: Strategic Growth and Financial Prudence